Welcome to our Q&A series on the latest comings and goings in the biotech and pharmaceutical industry. Every week, we highlight a notable executive change—like Ailux's recent appointment of Maria Belvisi as chief scientific officer. This feature aims to keep you informed about the talent shaping the future of medicine. Have a new hire or promotion? We encourage you to share the news with us so we can spread the word. Below, we answer common questions about this initiative and the latest move.
Who was recently hired as chief scientific officer at Ailux, and what is her background?
Ailux recently appointed Maria Belvisi as its new chief scientific officer. She brings extensive experience from AstraZeneca, where she served as senior vice president of research and development in respiratory and immunology within biopharmaceuticals R&D. Her expertise is expected to drive innovation at Ailux, particularly in areas related to respiratory diseases and immunology. The move underscores the company's commitment to strengthening its scientific leadership.
Why does STAT+ feature a different executive each week?
The weekly feature is designed to highlight significant personnel changes that may impact the industry. Each story focuses on a key figure—like a CSO or VP—whose move signals strategic shifts. By showcasing these individuals, we help readers understand the talent dynamics driving biotech and pharma. It also serves as a platform for organizations to announce their latest hires in a trusted publication, fostering transparency and networking within the sector.
How can companies share their executive changes with STAT+?
Organizations are encouraged to send details about new hires, promotions, or hard-to-fill positions to STAT+. The submission process is simple: just email the relevant information, including the person's name, new role, and previous position. The editorial team then reviews and integrates the news into the weekly feature. This is an excellent opportunity for companies to gain visibility among industry peers and talent seekers. Don't be shy—share your updates and help us build a comprehensive picture of industry movements.
What types of personnel changes are most relevant for this feature?
We welcome a wide range of changes, from C-suite appointments to promotions of rising stars. Examples include chief scientific officers, VPs of R&D, and department heads—especially in hard-to-fill roles. The focus is on positions that influence company strategy and innovation. Whether it's a biotech startup hiring its first CSO or a large pharma promoting a seasoned leader, we want to know. The goal is to highlight moves that matter to the community.
What was Maria Belvisi's previous role at AstraZeneca?
Before joining Ailux, Maria Belvisi held the position of senior vice president, research and development, respiratory & immunology at AstraZeneca's biopharmaceuticals R&D division. In this role, she oversaw the development of therapies for respiratory conditions like asthma and chronic obstructive pulmonary disease, as well as immunology programs. Her leadership contributed to several pipeline advancements. This experience makes her a valuable asset for Ailux as they pursue similar therapeutic areas.
Where can readers find the full story about Maria Belvisi and other executive moves?
The complete article, including more details on Maria Belvisi's appointment and other weekly highlights, is available exclusively to STAT+ subscribers. Readers can access the full story by continuing to STAT+ on the original page. The feature also includes additional insights on why these moves matter and what they mean for the industry. For those interested in following ongoing trends, subscribing to STAT+ provides regular updates on the dynamic world of biotech leadership.